Company Overview - Yuyuan Pharmaceutical Group Co., Ltd. (悦康药业) is a biopharmaceutical company focused on the research, development, production, and commercialization of therapies including oligonucleotides, mRNA vaccines, peptides, and innovative traditional Chinese medicine [4] - The company leverages its commercial product portfolio, cross-modal R&D technology platform, GMP-certified production system, and nationwide commercialization network to advance differentiated innovation pipelines in major therapeutic areas with unmet needs and long-term growth potential [4] - Key products include Yuyuan Tong® (Ginkgo biloba extract injection) for managing cerebrovascular and peripheral vascular disorders, Ailishi® (Citrate of Aildenafil tablets) for treating male erectile dysfunction, and other significant products like Liweike® (Omeprazole enteric-coated capsules) and Yuedaning® (Metformin sustained-release tablets) [4] Financial Performance - The company reported revenues of approximately RMB 4.52 billion, RMB 4.18 billion, RMB 3.77 billion, and RMB 1.30 billion for the fiscal years ending December 31, 2022, December 31, 2023, and 2024, and for the seven months ending July 31, 2025, respectively [10] - Gross profit figures were approximately RMB 2.87 billion, RMB 2.58 billion, RMB 2.15 billion, and RMB 596 million for the same periods, with corresponding gross profit margins of 63.5%, 61.6%, 56.9%, and 45.7% [12] - The company incurred a net loss of approximately RMB 146 million for the seven months ending July 31, 2025, primarily due to decreased revenue from cardiovascular products and significant investments in marketing and R&D activities [11] Industry Overview - The global and Chinese pharmaceutical markets are expected to continue expanding from 2020 to 2024, driven by increasing medical demand, a growing burden of chronic diseases, and ongoing improvements in drug innovation and access [13] - The top five therapeutic areas by revenue in 2024 globally will include digestive and metabolic, oncology, systemic anti-infectives, nervous system, and respiratory [14] - The cardiovascular drug market is projected to grow from USD 87.3 billion in 2020 to USD 106.5 billion in 2024, with a compound annual growth rate (CAGR) of 5.1%, expected to reach USD 165.5 billion by 2035 [19]

Group 1 - The core viewpoint of the article is that Yuyuan Pharmaceutical Group Co., Ltd. has submitted an application for listing on the Hong Kong Stock Exchange, with CITIC Securities as the sole sponsor [1] - Yuyuan Pharmaceutical is a biopharmaceutical company focused on the research, development, production, and commercialization of therapies including oligonucleotides, mRNA vaccines, peptides, and innovative traditional Chinese medicine [1] - The company leverages its commercial product portfolio, cross-modal R&D technology platform, GMP-certified production system, and nationwide commercialization network to advance differentiated innovative pipelines in major therapeutic areas with significant unmet needs and long-term growth potential [1]

Core Viewpoint - Yuyuan Pharmaceutical Group Co., Ltd. has submitted an application for listing on the Hong Kong Stock Exchange, with CITIC Securities as its sole sponsor, indicating its intention to expand its capital base for further growth in the biopharmaceutical sector [1] Group 1: Company Overview - Yuyuan Pharmaceutical is a biopharmaceutical company focused on the research, development, production, and commercialization of therapies in four modalities: oligonucleotides, mRNA vaccines, peptides, and innovative traditional Chinese medicine [1] - The company leverages a commercial product portfolio, cross-modal R&D technology platform, GMP-certified production systems, and a nationwide commercialization network to advance differentiated innovation pipelines in major therapeutic areas with significant unmet needs and long-term growth potential [1]

Core Viewpoint - Yuyuan Pharmaceutical Group Co., Ltd. has submitted an application for listing on the Hong Kong Stock Exchange, with CITIC Securities as its sole sponsor, indicating its intention to expand its capital base for further growth in the biopharmaceutical sector [1] Company Overview - Yuyuan Pharmaceutical is a biopharmaceutical company focused on the research, development, production, and commercialization of therapies in four modalities: oligonucleotides, mRNA vaccines, peptides, and innovative traditional Chinese medicine [1] - The company leverages a commercial product portfolio, cross-modal R&D technology platforms, GMP-certified production systems, and a nationwide commercialization network to advance differentiated innovation pipelines in major therapeutic areas with significant unmet needs and long-term growth potential [1]

悦康药业(688658.SH)发布公告，公司已于2025年12月29日向香港联交所递交了发行境外上市外资股(H 股)并在香港联交所主板挂牌上市的申请，并于同日在香港联交所网站刊登了本次发行上市的申请资 料。该申请资料为公司按照香港证监会及香港联交所的要求编制和刊发，为草拟版本，其所载资料可能 会适时作出更新及修订，投资者不应根据其中的资料作出任何投资决定。 ...

智通财经APP讯，悦康药业(688658.SH)发布公告，公司已于2025年12月29日向香港联交所递交了发行 境外上市外资股(H股)并在香港联交所主板挂牌上市的申请，并于同日在香港联交所网站刊登了本次发 行上市的申请资料。该申请资料为公司按照香港证监会及香港联交所的要求编制和刊发，为草拟版本， 其所载资料可能会适时作出更新及修订，投资者不应根据其中的资料作出任何投资决定。 ...

Core Viewpoint - Yuyuan Pharmaceutical Group Co., Ltd. has submitted an application for the issuance of H-shares and listing on the Hong Kong Stock Exchange, with the application materials published on the exchange's website [1][2]. Group 1 - The company submitted the application for H-share issuance and listing on December 29, 2025, and published the application materials on the Hong Kong Stock Exchange website [1]. - The application is intended for overseas investors and qualified domestic investors under Chinese laws, and will not be published on domestic exchanges [2]. - The issuance and listing are subject to approval from various regulatory bodies, including the China Securities Regulatory Commission and the Hong Kong Securities and Futures Commission, indicating potential uncertainties [3].

证券代码：688658 证券简称：悦康药业 公告编号：2025-060 悦康药业集团股份有限公司 关于向香港联交所递交 H 股发行上市申请 并刊发申请资料的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 悦康药业集团股份有限公司（以下简称"公司"）已于 2025 年 12 月 29 日向 香港联合交易所有限公司（以下简称"香港联交所"）递交了发行境外上市外资 股（H 股）并在香港联交所主板挂牌上市（以下简称"本次发行上市"）的申请， 并于同日在香港联交所网站刊登了本次发行上市的申请资料。该申请资料为公 司按照香港证券及期货事务监察委员会（以下简称"香港证监会"）及香港联交 所的要求编制和刊发，为草拟版本，其所载资料可能会适时作出更新及修订， 投资者不应根据其中的资料作出任何投资决定。 需要特别予以说明的是，本公告仅为境内投资者及时了解本次发行上市的 相关信息而作出。本公告以及刊登于香港联交所网站的申请资料均不构成也不 得视作对任何个人或实体收购、购买或认购公司本次发行的境外上市外资股 （H 股）的要约或要约邀请。 公 ...

人民财讯12月29日电，悦康药业(688658)12月29日公告，公司已于12月29日向香港联交所递交了发行境 外上市外资股(H股)并在香港联交所主板挂牌上市的申请，并于同日在香港联交所网站刊登了本次发行 上市的申请资料。 ...

据港交所文件，悦康药业集团股份有限公司向港交所提交上市申请书，独家保荐人为中信证券。 ...